trending Market Intelligence /marketintelligence/en/news-insights/trending/na5pwymc4q7z4cc6bez-xa2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Abbvie to continue manufacturing component for lymphoma drug

State Of Indonesian Online Video: Subscription

Virtual Multichannel Revenues Projected To Soar In Next Five Years

Street Talk Episode 45 - Fed Moving From Rate Hikes To Lower For Longer

Consumer Engagement Remains Challenging For OTT Players In Asia


Abbvie to continue manufacturing component for lymphoma drug

Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.

The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.

Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.